Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Theravance
Theravance
Irenic Capital urges Theravance to conduct review, add shareholder to board
Irenic Capital urges Theravance to conduct review, add shareholder to board
NASDAQ
Theravance
Irenic Capital
Flag link:
Theravance declares independence from GSK, crafts $250M plan to buy back its own shares
Theravance declares independence from GSK, crafts $250M plan to buy back its own shares
Endpoints
Theravance
GSK
Flag link:
Theravance gets a fresh start
Theravance gets a fresh start
EP Vantage
Theravance
GSK
Trelegy Ellipta
Royalty Pharma
Flag link:
Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results
Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results
BioSpace
Theravance
ampreloxetine
multiple system atrophy
neurogenic orthostatic hypotension
Flag link:
End-of-Year Restructuring Means Layoffs for These Companies
End-of-Year Restructuring Means Layoffs for These Companies
BioSpace
restructuring
Rigel Pharmaceuticals
Zymergen
Esperion Therapeutics
Amarin
Theravance
Sanofi
Acorda Therapeutics
CureVac
Ziopharm Oncology
Flag link:
Theravance axing 75% of staff, slashing R&D budget after flunking phase 3
Theravance axing 75% of staff, slashing R&D budget after flunking phase 3
Fierce Biotech
Theravance
layoffs
R&D
clinical trials
Flag link:
Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis
Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis
Endpoints
Theravance
izencitinib
ulcerative colitis
Crohn’s disease
clinical trials
Flag link:
Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903
Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903
Pharmaceutical Business Review
Theravance
COVID-19
clinical trials
acute lung injury
TD-0903
Flag link:
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Flag link:
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance
BioSpace
Pfizer
Theravance
JAK inhibitors
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
Layoffs Hit California Biopharma Companies
Layoffs Hit California Biopharma Companies
BioSpace
layoffs
Roche
Genentech
Pfizer
Aduro BioTech
Theravance
Merck
Flag link:
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
Yahoo/Zacks.com
Theravance
FDA
Yupelri
COPD
Flag link:
Mylan, Theravance win FDA approval for COPD drug
Mylan, Theravance win FDA approval for COPD drug
Biopharma Dive
Theravance
Mylan
Yupelri
COPD
FDA
Flag link:
FDA Action Alert: Theravance, Mallinckrodt and Aquestive
FDA Action Alert: Theravance, Mallinckrodt and Aquestive
BioSpace
FDA
Theravance
revefenacin
COPD
Mallinckrodt
MNK-812
Aquestive Therapeutics
AQST-199
erectile dysfunction
Flag link:
Theravance Biopharma and Cumberland Pharmaceuticals Enter into $25 Million Antibiotic Deal
Theravance Biopharma and Cumberland Pharmaceuticals Enter into $25 Million Antibiotic Deal
Xtalks
Cumberland Pharmaceuticals
Theravance
antibiotic
Vibativ
hospital-acquired bacterial pneumonia
Flag link:
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Motley Fool
JNJ
Remicade
TD-1473
Theravance
JAK inhibitors
inflammatory bowel disease
Flag link:
J&J strikes potential $1B JAK inhibitor deal with Theravance
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
Flag link:
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Flag link:
Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial
Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial
Drug Delivery Business News
Mylan
Theravance
COPD
clinical trials
revefenacin
Flag link:
Pages
1
2
3
4
5
6
7
8
9
next ›
last »